A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.C2GW7kSb.js ...

Analyst Kostas Biliouris of BMO Capital reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today.Don't Miss our Black Friday ...

Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...

The deal allows the Swiss company to develop cell therapies in-house. (The Wall Street Journal) Sarepta Therapeutics and ...

Arrowhead Pharmaceuticals is a biotechnology company focused on developing RNA interference (RNAi) therapeutics. Their proprietary platform, Targeted RNAi Molecule (TRiM™), allows them to target and ...

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET. Company Participants. Vince Anzalone - VP, IR Chris Anzalone - Preside ...

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.

Piper Sandler lowered the firm’s price target on Arrowhead (ARWR) to $45 from $62 and keeps an Overweight rating on the ...